MX2015016875A - Derivados de peptidos similares a peptido similar a glucagon 1 (glp-1) y sus usos. - Google Patents
Derivados de peptidos similares a peptido similar a glucagon 1 (glp-1) y sus usos.Info
- Publication number
- MX2015016875A MX2015016875A MX2015016875A MX2015016875A MX2015016875A MX 2015016875 A MX2015016875 A MX 2015016875A MX 2015016875 A MX2015016875 A MX 2015016875A MX 2015016875 A MX2015016875 A MX 2015016875A MX 2015016875 A MX2015016875 A MX 2015016875A
- Authority
- MX
- Mexico
- Prior art keywords
- derivatives
- glp
- peptides
- side chains
- relates
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 3
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 abstract 1
- 102400000324 Glucagon-like peptide 1(7-37) Human genes 0.000 abstract 1
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 abstract 1
- 239000013067 intermediate product Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13175094 | 2013-07-04 | ||
| US201361845646P | 2013-07-12 | 2013-07-12 | |
| PCT/EP2014/064033 WO2015000942A1 (en) | 2013-07-04 | 2014-07-02 | Derivatives of glp-1 like peptides, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015016875A true MX2015016875A (es) | 2016-04-07 |
Family
ID=48703344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015016875A MX2015016875A (es) | 2013-07-04 | 2014-07-02 | Derivados de peptidos similares a peptido similar a glucagon 1 (glp-1) y sus usos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9498534B2 (enExample) |
| EP (1) | EP3016975B1 (enExample) |
| JP (2) | JP6139712B2 (enExample) |
| KR (1) | KR20160029079A (enExample) |
| CN (1) | CN105377884B (enExample) |
| AR (1) | AR096789A1 (enExample) |
| AU (1) | AU2014286234A1 (enExample) |
| BR (1) | BR112015032875A2 (enExample) |
| CA (1) | CA2916311A1 (enExample) |
| MX (1) | MX2015016875A (enExample) |
| WO (1) | WO2015000942A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160021183A (ko) | 2013-06-20 | 2016-02-24 | 노보 노르디스크 에이/에스 | Glp-1 유도체 및 그것의 용도 |
| US9498534B2 (en) * | 2013-07-04 | 2016-11-22 | Novo Nordisk A/S | Derivatives of GLP-1 like peptides, and uses thereof |
| CN106999602B (zh) | 2014-11-27 | 2022-02-01 | 诺和诺德股份有限公司 | Glp-1衍生物及其用途 |
| JP6691125B2 (ja) | 2014-12-17 | 2020-04-28 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体及びその使用 |
| US10118904B2 (en) | 2015-06-05 | 2018-11-06 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of Demyelinating Diseases |
| PL3393496T3 (pl) | 2015-12-23 | 2024-04-22 | The Johns Hopkins University | Długo działający agonista glp-1r jako terapia stanów neurologicznych i neurodegeneracyjnych |
| WO2017149070A1 (en) | 2016-03-03 | 2017-09-08 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
| MA46780A (fr) | 2016-11-07 | 2019-09-11 | Novo Nordisk As | Esters à dchbs actif de composés peg et leur utilisation |
| WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
| WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
| WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
| CN108976147B (zh) * | 2017-05-31 | 2021-02-12 | 首都医科大学 | 氨基正己酰氨基甲环酰氨基正己酰碱性氨基酸，其合成，活性和应用 |
| CN109248323B (zh) * | 2017-07-14 | 2023-09-08 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
| BR112020001286A2 (pt) | 2017-07-19 | 2020-07-28 | Novo Nordisk A/S | composto, e, método de tratamento da diabetes, sobrepeso e/ou doenças cardiovasculares |
| EP3474820B1 (en) | 2017-08-24 | 2024-02-07 | Novo Nordisk A/S | Glp-1 compositions and uses thereof |
| JP7359358B2 (ja) * | 2017-11-30 | 2023-10-11 | グリアファーム エスエー | 神経疾患の予防及び治療に使用するためのポリケチド化合物及びその誘導体 |
| PE20211417A1 (es) | 2018-04-05 | 2021-08-02 | Sun Pharmaceutical Ind Ltd | Analogos novedosos de glp-1 |
| WO2019200594A1 (zh) | 2018-04-19 | 2019-10-24 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
| CN113024660B (zh) * | 2018-04-19 | 2023-07-14 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
| CN115814064A (zh) * | 2018-04-19 | 2023-03-21 | 杭州先为达生物科技有限公司 | Glp-1衍生物及其治疗用途 |
| CN112385033A (zh) * | 2018-07-12 | 2021-02-19 | 三菱电机株式会社 | 半导体装置 |
| CN116925237A (zh) | 2019-12-31 | 2023-10-24 | 北京质肽生物医药科技有限公司 | Glp-1和gdf15的融合蛋白以及其缀合物 |
| WO2021139744A1 (en) | 2020-01-11 | 2021-07-15 | Beijing Ql Biopharmaceutical Co., Ltd. | Conjugates of fusion proteins of glp-1 and fgf21 |
| PE20230819A1 (es) * | 2020-02-18 | 2023-05-19 | Novo Nordisk As | Composiciones y usos de glp-1 |
| JP2023545684A (ja) | 2020-09-30 | 2023-10-31 | ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド | ポリペプチドコンジュゲートおよび使用の方法 |
| CN114685644A (zh) * | 2020-12-29 | 2022-07-01 | 苏州康宁杰瑞生物科技有限公司 | 一种人glp-1多肽变体及其应用 |
| EP4288461A4 (en) | 2021-07-14 | 2025-07-02 | Beijing Ql Biopharmaceutical Co Ltd | FUSION POLYPEPTIDES FOR METABOLIC DISORDERS |
| CA3252113A1 (en) | 2022-03-30 | 2023-10-05 | Beijing Ql Biopharmaceutical Co Ltd | Liquid pharmaceutical compositions of polypeptide conjugates and their methods of use |
| EP4642440A1 (en) | 2022-12-30 | 2025-11-05 | Algipharma As | Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6458924B2 (en) * | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| ATE466027T1 (de) * | 1998-02-27 | 2010-05-15 | Novo Nordisk As | Abkömmlinge von glp-1 analogen |
| HUP0200297A3 (en) | 1999-03-17 | 2002-09-30 | Novo Nordisk As | Method for acylating peptides and the glutaminic acid derivatives as acylating agents |
| EP1076066A1 (en) * | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| AU1269501A (en) | 1999-11-12 | 2001-05-30 | Novo Nordisk A/S | Use of glp-1 agonists for the inhibition of beta cell degeneration |
| GB0020551D0 (en) | 2000-08-22 | 2000-10-11 | Birkett David | Sprinkler system |
| BRPI0407936A (pt) | 2003-03-19 | 2006-02-21 | Lilly Co Eli | composto de glp-1 peguilado, método de estimular o receptor de glp-1 em um indivìduo, e, uso de composto glp-1 peguilado |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| EA012442B1 (ru) | 2005-05-13 | 2009-10-30 | Эли Лилли Энд Компани | Пегилированные соединения glp-1 |
| EP2514406A1 (en) | 2007-06-01 | 2012-10-24 | Novo Nordisk A/S | Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier |
| WO2009030771A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| WO2009030738A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| CN102333788A (zh) | 2009-02-19 | 2012-01-25 | 诺沃—诺迪斯克有限公司 | 因子viii的修饰 |
| JP6006118B2 (ja) | 2009-12-16 | 2016-10-12 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アナログ及び誘導体 |
| US9708383B2 (en) | 2010-11-09 | 2017-07-18 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
| CA2832811A1 (en) * | 2011-04-12 | 2012-10-18 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| US9498534B2 (en) * | 2013-07-04 | 2016-11-22 | Novo Nordisk A/S | Derivatives of GLP-1 like peptides, and uses thereof |
-
2014
- 2014-07-02 US US14/322,077 patent/US9498534B2/en active Active
- 2014-07-02 BR BR112015032875A patent/BR112015032875A2/pt not_active Application Discontinuation
- 2014-07-02 CA CA2916311A patent/CA2916311A1/en not_active Withdrawn
- 2014-07-02 JP JP2015563070A patent/JP6139712B2/ja active Active
- 2014-07-02 CN CN201480038380.6A patent/CN105377884B/zh active Active
- 2014-07-02 AR ARP140102467A patent/AR096789A1/es unknown
- 2014-07-02 WO PCT/EP2014/064033 patent/WO2015000942A1/en not_active Ceased
- 2014-07-02 MX MX2015016875A patent/MX2015016875A/es unknown
- 2014-07-02 EP EP14734816.3A patent/EP3016975B1/en active Active
- 2014-07-02 KR KR1020167002151A patent/KR20160029079A/ko not_active Withdrawn
- 2014-07-02 AU AU2014286234A patent/AU2014286234A1/en not_active Abandoned
-
2016
- 2016-09-28 US US15/278,501 patent/US10010614B2/en active Active
-
2017
- 2017-02-09 JP JP2017022249A patent/JP6687557B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017105819A (ja) | 2017-06-15 |
| US9498534B2 (en) | 2016-11-22 |
| JP6687557B2 (ja) | 2020-04-22 |
| JP2016528163A (ja) | 2016-09-15 |
| US10010614B2 (en) | 2018-07-03 |
| US20170007707A1 (en) | 2017-01-12 |
| WO2015000942A1 (en) | 2015-01-08 |
| EP3016975A1 (en) | 2016-05-11 |
| AU2014286234A1 (en) | 2015-12-17 |
| EP3016975B1 (en) | 2019-01-16 |
| CA2916311A1 (en) | 2015-01-08 |
| CN105377884B (zh) | 2021-07-20 |
| CN105377884A (zh) | 2016-03-02 |
| JP6139712B2 (ja) | 2017-05-31 |
| KR20160029079A (ko) | 2016-03-14 |
| AR096789A1 (es) | 2016-02-03 |
| BR112015032875A2 (pt) | 2017-11-07 |
| US20150011462A1 (en) | 2015-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015016875A (es) | Derivados de peptidos similares a peptido similar a glucagon 1 (glp-1) y sus usos. | |
| MX2015016564A (es) | Derivados de peptido similar al glucaton tipo 1 (glp-1) y uso de los mismos. | |
| ZA201903667B (en) | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers | |
| MY181181A (en) | Fgf21 derivatives and uses thereof | |
| PH12014501924A1 (en) | Xten conjugate compositions and methods of making same | |
| MX2019000566A (es) | Suministro mediado por ve de conjugados de proteína de enlace-molécula pequeña. | |
| WO2011075393A3 (en) | Glucagon/glp-1 receptor co-agonists | |
| ZA201805336B (en) | Amanitin conjugates | |
| MX2016006053A (es) | Compuestos selectivos de peptido yy (pyy) y usos de los mismos. | |
| MX2016007063A (es) | Peptidos terapeuticos. | |
| PH12018502742A1 (en) | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof | |
| MY210315A (en) | Cnp prodrugs | |
| MX2020009857A (es) | Conjugados de interleucina-2 (il-2). | |
| MX2016007865A (es) | Peptidos citotoxicos y conjugados de los mismos. | |
| MA40030A (fr) | Conjugués peptide-médicament | |
| HK1215595A1 (zh) | 白細胞介素-10藥物組合物和使用方法 | |
| NZ623294A (en) | Stabilized alpha-galactosidase and uses thereof | |
| MX2015006998A (es) | Una composicion acuosa estable que comprende insulina humana o un analogo o derivado de la misma. | |
| EP4372002A3 (en) | Proximity-based sortase-mediated protein purification and ligation | |
| PH12020550105A1 (en) | Long-acting conjugates of glp-2 derivatives | |
| PH12018501351A1 (en) | Cortistatin analogs and uses thereof | |
| CY1123041T1 (el) | Συνδυασμος κανρενοατης και εξενατιδης | |
| PT3888647T (pt) | Composição farmacêutica que contém inibidor duplo de ezh1/2 para ser utilizado como fármaco de combinação | |
| MX2021003908A (es) | Polipeptidos de accion prolongada y metodos para su produccion y administracion. | |
| NZ595060A (en) | Treatment of cancer with immunostimulatory hiv tat derivative polypeptides |